Hardman Johnston Global Advisors, an investment management company, released its “Hardman Johnston Large Cap Equity Strategy” ...

This was the stock's third consecutive day of losses.

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $482.4, with a high estimate of $567.00 and a low estimate of $420.00. This current average ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

The leading Cystic Fibrosis Companies such as Verona Pharma, Armata Pharmaceuticals, 4D Molecular Therapeutics, Spirovant ...

The stock's fall snapped a three-day winning streak.

According to a Worker Adjustment Retraining Notification written by Vertex to the R.I. Department of Labor and Training, ...

Vertex Pharmaceuticals is laying off 125 employees and consolidating their Rhode Island buildings after a failed diabetes ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the 13 Biotech Stocks with Huge Upside Potential. The company ...

Vertex Pharmaceuticals is laying off workers and consolidating its real estate footprint in Rhode Island after ending a ...